Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 4Phase NA 2Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Head & Neck 3Gastrointestinal 3NET 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Ovarian Neoplasms 325Uterine Cervical Neoplasms 131Endometrial Neoplasms 109Breast Neoplasms 99Carcinoma, Non-Small-Cell Lung 85Fallopian Tube Neoplasms 77Colorectal Neoplasms 74Carcinoma, Ovarian Epithelial 71Neoplasms 63Pancreatic Neoplasms 62Stomach Neoplasms 59Melanoma 57Neoplasm Metastasis 51Triple Negative Breast Neoplasms 49Squamous Cell Carcinoma of Head and Neck 43Prostatic Neoplasms 42Lung Neoplasms 41Esophageal Neoplasms 40Head and Neck Neoplasms 39Urinary Bladder Neoplasms 32Carcinoma, Renal Cell 31Sarcoma 29Recurrence 28Small Cell Lung Carcinoma 26Colonic Neoplasms 25Carcinoma, Hepatocellular 24Carcinoma, Transitional Cell 20Uterine Neoplasms 16Peritoneal Neoplasms 15Mesothelioma 15

Interventions

Drug Therapy 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasms, Glandular and Epithelial × Gynecologic × Clear all
NCT02759588 2023-01-05

GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

Genelux Corporation

Phase 1/2 Completed
46 enrolled
Gynecologic

Carcinoma, Fallopian Tube Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Poxviridae Infections, Vaccinia, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡